Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ketorolac
Drug ID BADD_D01232
Description Ketorolac is a Non-steroidal anti-inflammatory drug (NSAID) and is commercially available as an oral tablet, injectable, nasal spray and as an ophthalmic solution.[L6358][L6508][L11055][L3674][L11070] It's analgesic properties make it a useful pain management tool across many settings including postoperative pain, rheumatoid arthritis, osteoarthritis, menstrual disorders, headaches, spinal and soft tissue pain, and ankylosing spondylitis.[L6520] Impressively, ketorolac has a similar efficacy to standard doses of morphine and meperidine making it a useful opioid sparing agent.[L6511]
Indications and Usage For the short-term (~5 days) management of moderately severe acute pain that requires analgesia at the opioid level, usually in a postoperative setting.
Marketing Status Not Available
ATC Code M01AB15; S01BC05
DrugBank ID DB00465
KEGG ID D08104
MeSH ID D020910
PubChem ID 3826
TTD Drug ID D0D9JW
NDC Product Code Not Available
Synonyms Ketorolac
Chemical Information
Molecular Formula C15H13NO3
CAS Registry Number 74103-06-3
SMILES C1CN2C(=CC=C2C(=O)C3=CC=CC=C3)C1C(=O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Vasculitis24.05.02.001; 10.02.02.006--
Vertigo17.02.12.002; 04.04.01.003--
Vision blurred06.02.06.007; 17.17.01.0100.001837%
Visual impairment06.02.06.0080.000459%Not Available
Vomiting07.01.07.0030.002526%
Weight increased13.15.01.0060.000459%
Wheezing22.03.01.0090.000689%
Tubulointerstitial nephritis20.05.02.002--Not Available
Hypoacusis04.02.01.006--
Contusion12.01.06.001; 24.07.06.001; 23.03.11.002; 15.03.01.0080.000459%
Post procedural haemorrhage24.07.01.014; 12.02.05.004--
Wound haemorrhage24.07.01.029; 12.01.08.017--Not Available
Rhinalgia22.02.05.032--Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.015--Not Available
Conjunctival hyperaemia06.04.01.004--Not Available
Ear discomfort04.03.01.0050.000459%Not Available
Eye pruritus06.04.05.0060.000459%Not Available
Nasal discomfort22.02.05.0200.004823%Not Available
Protein urine present13.13.02.006--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Corneal thinning06.06.03.009--Not Available
Haemorrhage24.07.01.0020.001148%Not Available
Cystoid macular oedema12.02.02.005; 06.04.06.0100.000459%Not Available
Epidermal necrosis23.03.03.035--Not Available
Urine output increased13.13.03.002--Not Available
Hepatic enzyme increased13.03.01.019--Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Ill-defined disorder08.01.03.049--Not Available
Psychotic disorder19.03.01.002--
Pulmonary function test decreased13.19.01.001--Not Available
The 7th Page    First    Pre   7 8    Next   Last    Total 8 Pages